Daraxonrasib Drug Demonstrates Significant Survival Improvement in Pancreatic Cancer Trial

A new drug, daraxonrasib, is being recognized as a major advancement in pancreatic cancer treatment. Experts at a recent conference reported that the drug nearly doubled survival outcomes in a key clinical trial. While promising, clinicians anticipate challenges related to high costs and managing patient expectations for this significant development.